A field note should let another person understand exactly what was observed. In this case the documented offer is BlueChew MAX, meaning sildenafil 45 mg plus tadalafil 18 mg in a sublingual tablet. The review keeps product identity, advertised terms and open questions in separate entries. It is a record of public information, not a report from a patient visit.
Availability: Provider article lists a new-customer option; assessment required.
The exact product
The distinguishing observation is a two-drug combination without GOLD’s additional actives. Record the full active list and supplied form before summarizing the product as a pill, chew or ED treatment. Those short categories lose information that may matter to a pharmacist. A later prescription can differ from the listing, so keep the advertised record and the dispensed label identifiable. Neither should silently replace the other in a treatment history.
| Provider | BlueChew |
|---|---|
| Listed active ingredients | Sildenafil 45 mg + tadalafil 18 mg |
| Dosage form | Compounded sublingual tablet |
| Regulatory distinction | Compounded preparation; the finished product is not FDA-approved. |
| Source basis | BlueChew: product-specific approximate costs · BlueChew: combination and single-ingredient formulas · BlueChew: product access and legacy-plan notice |
Price, supply and payment
The price observation is Article example: about $40 / 4 monthly doses. Attach a quantity and billing period only where the source provides them together. Keep any calculated monthly equivalent separate from the actual payment schedule. If the figure is approximate, a starting price or unmatched to a complete plan, preserve that qualifier. A useful financial note shows the limit of the observation instead of making the blank fields look complete.
| Approximate cost article | 4 monthly doses around $40; 24 around $135 |
|---|---|
| Separate unit headline | $5.63 needs its matching quantity confirmed |
| New-customer notice | MAX and GOLD named as options for new customers |
| Different from VMAX | MAX uses sildenafil, not vardenafil |
What the research can support
The evidence entry reads: research on a different tadalafil/sildenafil regimen, not a MAX trial. The unanswered part is matching onset endpoints and finished-formula comparative data. Record the studied population, preparation and outcome before linking research to a commercial product. An abstract can establish what its authors reported while leaving methods unavailable for full appraisal. A provider's own survey belongs in a different category from a randomized comparison; a field note should make that source difference easy to see.
| Evidence boundary | research on a different tadalafil/sildenafil regimen, not a MAX trial |
|---|---|
| Not established here | matching onset endpoints and finished-formula comparative data |
| Clinical and regulatory references | EAU: Management of erectile dysfunction · Cui et al. (2015): daily tadalafil with as-needed sildenafil · MedlinePlus: Tadalafil · DailyMed: Tadalafil prescribing information, including section 5.11 · FDA: Compounding and the FDA — questions and answers · MedlinePlus: Sildenafil |
Safety questions for the prescriber
Use the medication list as a reconciliation document. It should include nitrate or nitrite use, riociguat, other ED treatments, blood-pressure drugs and relevant medical conditions. Do not mark BlueChew MAX as cleared merely because a prior ED drug was tolerated. The clinician must consider the actual formula and history. Record the instructions received rather than deriving a dose, overlap or switching interval from this review.
| Multiple PDE5 inhibitors | Standard tadalafil labeling advises against combining PDE5 inhibitors; individualized rationale and monitoring are needed. |
|---|
Availability and the actual prescription
The access observation is time-specific: Provider article lists a new-customer option; assessment required. Distinguish a public catalog entry, a safety-library entry, an account offer and a clinician-approved prescription. They are four different states. If support supplies a clarification, save the date and exact product name. A link that opens successfully proves only that a page is reachable, not that enrollment or dispensing has been verified.
Refills, changes and cancellation
When the plan changes, create a new entry rather than overwriting the old one. Note who advised the change, which prescription it concerns and what happens to the next order. A useful question to carry forward is “What is the intended benefit of combining these two ingredients at the prescribed strengths?” Keep clinical response notes separate from shipment and payment confirmations. This makes it easier to identify an unresolved handoff before a refill proceeds on outdated assumptions.
| Hold choices | A one-order skip differs from an indefinite stop-until-return setting. |
|---|---|
| Cancellation notice | At least 24 hours before renewal in the published policy. |
| Clinical plan changes | Account FAQ requests 48 hours; changes do not affect an order already processing. |
| Returns | Prescription returns are not accepted. |
| Policy sources | BlueChew: account and subscription questions · BlueChew: returns and refunds policy |
Compare named products
The related reviews serve as cross-references, not endorsements. Compare a named field such as active list, dosage form or payment term and state why the difference matters. Do not infer a matching strength from a similar product name. If a proposed alternative has an unverified current plan, retain that uncertainty in the comparison instead of treating the alternative as immediately obtainable.
Questions to keep with the offer
The final field is the boundary of the investigation. We read the cited documents but did not order BlueChew MAX, inspect a pharmacy, test support or observe clinical outcomes. That boundary belongs in the record as much as the ingredients do. New account or prescribing information can update the practical decision; it does not retroactively turn this public-document review into a firsthand assessment.
| Ask about this formula | What is the intended benefit of combining these two ingredients at the prescribed strengths? |
|---|---|
| Ask about the payment | What are the exact quantity, total due now, renewal amount and notice deadline? |
| Ask about a change | Who confirms the medical instructions, pharmacy order and next account charge? |
When to get urgent help
An erection lasting more than four hours or chest pain requires emergency care. Tell the treating clinician what was taken and when.
Sudden hearing or vision loss needs prompt medical attention. Do not wait for an ordinary account-support reply.
Back to all individual product reviews
Trace the information
Checked October 7, 2026. Provider pages establish advertised claims. Medical sources supply general context; citation does not imply endorsement.
- BlueChew: product-specific approximate costsProvider price examples; approximate and not necessarily consistent with other offer pages
- BlueChew: combination and single-ingredient formulasProvider article; listed strengths and formulations, not independent comparative evidence
- BlueChew: product access and legacy-plan noticeProvider article; restricts certain products to existing enrolled customers; confirm account eligibility
- BlueChew: account and subscription questionsProvider policy; plan changes, one-order skips, and indefinite holds
- BlueChew: shipping and delivery questionsProvider policy; destination availability, shipping, and renewal terms
- BlueChew: returns and refunds policyProvider policy; prescription returns and 24-hour cancellation notice
- EAU: Management of erectile dysfunctionSpecialty guideline; clinical evaluation, treatment, and limited combination evidence
- Cui et al. (2015): daily tadalafil with as-needed sildenafilPrimary clinical study; 180 patients, specific regimen, abstract reviewed via NCBI
- MedlinePlus: TadalafilDrug information; standard tadalafil products
- DailyMed: Tadalafil prescribing information, including section 5.11Prescribing label; not evidence for the 4Play combination
- FDA: Compounding and the FDA — questions and answersGovernment guidance on compounded medications
- MedlinePlus: SildenafilDrug information; standard sildenafil products